Dengue vaccine study
Tuesday, 02 September, 2008
Avantogen [ASX: ACU] investee Hawaii Biotech will receive clinical trial support from the US Walter Reed Army Institute of Research (WRAIR) for its dengue fever vaccine program.
WRAIR has considerable experience with dengue fever and an established track record in emerging infectious diseases.
The recombinant-DNA-based vaccine candidate will soon undertake the clinical trial process.
Incidents of dengue, a close relative of the West Nile virus, are now growing rapidly in Australia and the Asian region.
Heart muscle regeneration genes mapped
Researchers have uncovered insights into how stem cells develop and mature into heart muscle...
The cause of 2022's mpox outbreak revealed
Researchers have discovered that the strain of mpox behind the 2022 outbreak was a weakened form...
New gene therapy treats liver disorder in growing children
Researchers have developed a genome-editing approach that repairs a faulty gene directly at its...
